Arno Therapeutics (ARNI) Stock Price & Analysis
ARNI Stock Chart & Stats
- Day’s Range
- $0.00 - $0.01
- 52-Week Range
- $0.00 - $0.01
- Previous Close
- $0.01
- Volume
- N/A
- Average Volume (3M)
- 615.78K
- Market Cap
- $4,984
- Enterprise Value
- N/A
- Total Cash (Recent Filing)
- $2.12M
- Total Debt (Recent Filing)
- $5,088
- Price to Earnings (P/E)
- 0.0
- Beta
- -34.46
- Next Earnings
- N/A
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
ARNI FAQ
What was Arno Therapeutics’s price range in the past 12 months?
What is Arno Therapeutics’s market cap?
When is Arno Therapeutics’s upcoming earnings report date?
Is Arno Therapeutics overvalued?
Does Arno Therapeutics pay dividends?
What is Arno Therapeutics’s EPS estimate?
How many shares outstanding does Arno Therapeutics have?
Which hedge fund is a major shareholder of Arno Therapeutics?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Arno Therapeutics
Arno Therapeutics, Inc., headquartered in Flemington, New Jersey, operates as a biopharmaceutical enterprise focused on discovering and advancing treatments for cancer and other severe health conditions. The company's developmental portfolio includes several key compounds: Onapristone, a type 1 anti-progestin hormone blocker, is currently undergoing Phase I/II clinical trials. This therapeutic is being investigated for its efficacy in treating various solid tumors, such as breast and endometrial cancers in post-menopausal women, and advanced castration-resistant prostate cancer in men. AR-12, an orally administered cancer therapy, has successfully completed Phase I clinical studies for solid tumors and hematological malignancies. Additionally, it is in pre-clinical development for potential applications against a range of microbial targets. AR-42, another innovative oral cancer treatment, is involved in a Phase I investigator-initiated clinical study, targeting both hematological malignancies and solid tumors. To support its research and development efforts, Arno Therapeutics has established licensing agreements with Invivis Pharmaceuticals, Inc., the Regents of the University of Minnesota, and the Ohio State University Innovation Foundation. The company also holds a co-development partnership with Leica Biosystems Newcastle Ltd.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- David M. Tanen
- Employees
- 4
- Website
- www.arnothera.com
- Address
- 200 Route 31 North, Flemington, NJ, 08822, US
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 3 | 3 | 5 |
| Technical Analysis | 1 | 1 | 3 |
| Moving Averages | 2 | 2 | 2 |
